Browse News
Filter News
Found 170 articles
-
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
4/16/2024
Boehringer Ingelheim announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
-
SPEVIGO® approved for expanded indications in China and the US
3/19/2024
Boehringer Ingelheim announced that the US FDA has approved SPEVIGO® injection for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s recent approval of SPEVIGO® for the reduction of occurrence of generalized pustular psoriasis in adolescents from 12 years of age with a body weight ≥40 kg and adults.
-
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
3/11/2024
Boehringer Ingelheim and Sosei Group Corporation announced they have entered a global collaboration and exclusive option-to-license agreement.
-
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
3/7/2024
Boehringer Ingelheim announced it will cap out-of-pocket costs at $35 per month for eligible patientsi for all the company's inhaler products.
-
Boehringer Ingelheim and Zealand Pharma’s dual glucagon/GLP-1 receptor agonist elicited significant topline Phase II results in metabolic dysfunction-associated steatohepatitis.
-
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
2/26/2024
Boehringer Ingelheim announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase II trial [response difference: 64.8% (CI 51.1% - 78.6%), p<0.0001].
-
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
2/26/2024
Zealand Pharma A/S announced that Boehringer Ingelheim has reported that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase 2 trial [response difference: 64.8% (CI 51.1% - 78.6%), p-value (p<0.0001)].
-
New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses
2/19/2024
A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
-
Boehringer Ingelheim Partners with Veeva to Advance its Clinical and Regulatory Operations in Animal Health
2/14/2024
Veeva Systems announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit.
-
Boehringer expands production site in Greece for new medicine
1/11/2024
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced a further expansion and upgrade of its plant in Koropi, Greece.
-
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
1/3/2024
Suzhou Ribo Life Science Co., Ltd. and Ribocure AB announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis.
-
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy
12/6/2023
CDR-Life Inc. announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy.
-
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
11/23/2023
Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO®, marking a significant step for the treatment of feline diabetes in Europe.
-
Novel AI-Driven Model Validated to Predict Risk of Chronic Kidney Disease Progression in Large U.S. Study
11/4/2023
Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a machine-learning tool developed to predict the risk of chronic kidney disease progression at all stages of the disease.
-
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
10/30/2023
Burning Rock Biotech Limited is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement in the field of oncology companion diagnostics.
-
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
10/25/2023
In a unique partnership, Boehringer Ingelheim Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis related to interstitial lung disease.This collaboration marks a significant leap forward in patient-centric care, driven by empathy and understanding.
-
Talent Acquisition Turns Introspective in a Cooler Market, and Other Things We Learned at LEAP TA...
10/18/2023
Life sciences talent acquisition teams are examining internal processes and thinking critically about their employer value proposition as they prepare for innovation and market swings. -
Remedium selected as finalist for Boehringer Ingelheim Innovation Day
10/16/2023
Remedium Bio is excited to announce that the company has been selected as a finalist for the in-person pitch competition at the upcoming Boehringer Ingelheim External Innovation Day.
-
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
10/5/2023
Boehringer Ingelheim and Zealand Pharma A/S announced the initiation of three Phase III trials investigating survodutide for people living with overweight or obesity.
-
The Scleroderma Research Foundation (SRF) Announces Second Partnership for Conquest Trial Platform
10/3/2023
The Scleroderma Research Foundation, the nation's largest non-profit funder of scleroderma research, announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.